MIURA Masatomo

写真a

Affiliation

Graduate School of Medicine  Doctorial Course in Medicine  Bioregulatory Medicine  Department of Pharmacokinetics

Research Interests 【 display / non-display

  • 薬物動態学

  • 臨床薬理学

Graduating School 【 display / non-display

  •  
    -
    1992.03

    Tohoku Pharmaceutical University   Faculty of Pharmaceutical Science   Graduated

Graduate School 【 display / non-display

  •  
    -
    1994.03

    Tohoku Pharmaceutical University  Graduate School, Division of Pharmaceutical Sciences  Master's Course  Completed

Campus Career 【 display / non-display

  • 2021.12
    -
    Now

    Akita University   Graduate School of Medicine   Doctorial Course in Medicine   Bioregulatory Medicine   Department of Pharmacokinetics   Professor  

  • 2013.04
    -
    2021.11

    Akita University   Hospital   Department of Pharmacy   Professor  

 

Research Achievements 【 display / non-display

    ◆Original paper【 display / non-display

  • Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

    Masatomo,Miura

    Ther Drug Monit   29 ( 299 ) 304   2007.01

    Research paper (journal)   Single author

  • Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

    Masatomo,Miura

    Eur J Clin Pharmacol   63 ( 279 ) 288   2007.01  [Refereed]

    Research paper (journal)   Single author

  • Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography

    Masatomo,Miura

    J Pharm Biomed Anal   43 ( 741 ) 745   2007.01

    Research paper (journal)   Single author

  • Pharmacokinetics of fexofenadine enantiomers in healthy subjects

    Masatomo,Miura

    Chirality   19 ( 223 ) 227   2007.01

    Research paper (journal)   Single author

  • ◆Other【 display / non-display

  • Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia

    Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto

    Cancer Chemotherapy and Pharmacology ( Springer Nature )    2024

    CiNii Research

  • Evaluation of Plasma Concentrations of Mycophenolic Acid in Renal Transplant Patients Using LM1010 High-performance Liquid Chromatography

    Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo

    YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan )  143 ( 4 ) 377 - 383   2023

    DOI PubMed CiNii Research

  • Determination of Plasma Concentrations of Imatinib by a Novel Automated Analyzer Based on High-Performance Liquid Chromatography

    Fukushi Yayoi, Akamine Yumiko, Matsushita Miyuki, Morikawa Satoru, Miura Masatomo

    YAKUGAKU ZASSHI ( The Pharmaceutical Society of Japan )  143 ( 11 ) 963 - 969   2023

    DOI CiNii Research

  • An Investigational Study to Establish the Basic Construction of Precision Medicine from a Pharmaceutical Perspective

    Tsuji Daiki, Saito Yoshiro, Mushiroda Taisei, Miura Masatomo, Hira Daiki, Terada Tomohiro

    Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) ( Japanese Society of Pharmaceutical Health Care and Sciences )  46 ( 2 ) 66 - 76   2020

    <p>Given that the cancer gene panel test was approved in June 2019, precision medicine based on the information about somatic mutation is expected to be widely available. Similarly, pharmacogenomics (PGx) associated with germline genes, such as drug-metabolizing enzymes, could also be effective tools. However, its clinical implementation has been delayed.</p><p>To address this issue, we conducted a survey regarding pharmacists' involvement in "cancer genomic medicine (CGM)" and actual use of PGx and therapeutic drug monitoring (TDM). The response rate of the survey was 96.8% (121/125).</p><p>According to this survey, genetic polymorphism analysis for irinotecan (UGT1A1), which is approved for genetic testing, was most commonly used. Among the tests not covered by insurance, tacrolimus (CYP3A5) and voriconazole (CYP2C19) were commonly used. Only a few facilities conducted PGx tests. Unlike PGx, many drugs are covered by insurance for TDM, which was commonly used. Vancomycin was most commonly used, followed by teicoplanin and cyclosporine. Regarding CGM, it was found that the pharmacists were most commonly involved in dose adjustment support, followed by support for selection of anti-cancer agents. Pharmacists' participation in the expert panel was 21.3%.</p><p>This survey revealed that PGx testing is less common compared with TDM. PGx of drug-metabolizing enzymes could potentially influence adverse reactions and efficacy. It might be possible to provide individualized pharmacotherapy if PGx testing could be performed at the same time as gene panel tests. Insurance-covered PGx testing may increase in the future if more high-quality clinical trials are conducted and its usefulness is validated.</p>

    DOI CiNii Research

  • Personalized medicine for oral molecular-targeted anticancer drugs

    Miura Masatomo

    Folia Pharmacologica Japonica ( The Japanese Pharmacological Society )  153 ( 2 ) 73 - 78   2019

    <p>Therapeutic drug monitoring (TDM) is carried out by evaluating drug plasma (or serum) concentrations in response to individual optimal treatments by dose adjustment to improve efficacy or avoid side effects. Many molecular-targeted anticancer drugs show exposure-efficacy and exposure-toxicity relationships. Therefore, plasma concentrations of anticancer drugs can be used as biomarkers. However, to carry out TDM, therapeutic target ranges indicating exposure-response (efficacy/toxicity) relationships must be determined. In Japan, treatment fees for managing the TDM of imatinib and sunitinib have been assessed since 2012 and 2018, respectively. In therapy for imatinib or sunitinib using TDM, reduced toxicity, discontinuation rates, and costs for treatments as well as improved clinical efficacy have been noted. To establish the use of TDM in clinical practice, it is necessary to determine target plasma concentrations (minimum effective concentration or minimum toxic concentration) of many molecular-targeted anticancer drugs by retrospective and prospective clinical trials. In these clinical trials, analytical methods with high precision are needed. By carrying out TDM, we may determine the optimal anticancer therapy for patients as precision medicine after the start of therapy.</p>

    DOI PubMed CiNii Research

  • display all >>

Grant-in-Aid for Scientific Research 【 display / non-display

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2020.04  -  2022.03